Daily Endocrinology Research Analysis
Three studies shape current endocrinology practice and science: (1) discovery of recessive TMEM167A variants causing neonatal diabetes with microcephaly/epilepsy and defining an ER-to-Golgi trafficking mechanism in β cells; (2) a refined LC-MS/MS newborn screening algorithm for 21-hydroxylase deficiency that nearly eliminates low-birth-weight false positives while preserving sensitivity; (3) a meta-analysis showing dual incretin/glucagon agonist survodutide significantly lowers HbA1c and body we
Summary
Three studies shape current endocrinology practice and science: (1) discovery of recessive TMEM167A variants causing neonatal diabetes with microcephaly/epilepsy and defining an ER-to-Golgi trafficking mechanism in β cells; (2) a refined LC-MS/MS newborn screening algorithm for 21-hydroxylase deficiency that nearly eliminates low-birth-weight false positives while preserving sensitivity; (3) a meta-analysis showing dual incretin/glucagon agonist survodutide significantly lowers HbA1c and body weight, with dose–duration effects and increased gastrointestinal adverse events.
Research Themes
- Genetic endocrinology and monogenic diabetes mechanisms
- Optimization of endocrine newborn screening diagnostics
- Incretin-based obesity pharmacotherapy efficacy and safety
Selected Articles
1. Recessive TMEM167A variants cause neonatal diabetes, microcephaly, and epilepsy syndrome.
Genome sequencing in six patients identified biallelic TMEM167A variants as a new genetic cause of MEDS, with universal neonatal diabetes and severe microcephaly and frequent epilepsy. Functional studies in EndoC-βH1 and iPSC-derived β cells showed that TMEM167A loss or a patient variant impairs ER-to-Golgi trafficking, sensitizes β cells to ER stress, disrupts proinsulin trafficking, and causes β-cell dysfunction.
Impact: This study identifies a novel disease gene and mechanism linking ER-to-Golgi trafficking to β-cell failure in neonatal diabetes, advancing monogenic diabetes diagnostics and biology.
Clinical Implications: Adds TMEM167A to genetic panels for neonatal diabetes/MEDS, enabling earlier diagnosis and counseling; suggests ER-stress–targeted strategies could be explored for β-cell protection.
Key Findings
- Six individuals with biallelic TMEM167A variants had neonatal diabetes and severe microcephaly; five had epilepsy.
- TMEM167A is highly expressed in human pancreas and brain.
- TMEM167A knockdown or patient p.Val59Glu variant increased β-cell ER stress sensitivity and impaired proinsulin trafficking to the Golgi.
- iPSC-derived β cells carrying p.Val59Glu exhibited functional defects consistent with diabetes.
Methodological Strengths
- Integration of human genetics with mechanistic validation in EndoC-βH1 and iPSC-derived β cells
- Convergent assays of ER stress and proinsulin trafficking demonstrating causality
Limitations
- Small patient cohort (n=6) limits generalizability and phenotype spectrum
- Lack of in vivo animal modeling to assess systemic and developmental impacts
Future Directions: Expand cohort studies to define penetrance and spectrum; develop animal models; explore ER-stress modulators or trafficking-corrective strategies as potential therapeutics.
Understanding the genetic causes of diseases that affect pancreatic β cells and neurons can give insights into pathways essential for both cell types. Microcephaly, epilepsy, and diabetes syndrome (MEDS) is a congenital disorder with two known etiological genes, IER3IP1 and YIPF5. Both genes encode proteins involved in endoplasmic reticulum (ER) to Golgi trafficking. We used genome sequencing to identify 6 individuals with MEDS caused by biallelic variants in the potentially novel disease gene TMEM167A. All had neonatal diab
2. Enhancing Accuracy of Newborn Screening for 21OHD: Strategic Use of 21-Deoxycortisol in a Large-Scale Tokyo Cohort.
In a prospective cohort of 326,006 newborns, the authors evaluated an LC-MS/MS second-tier algorithm for 21OHD that maintained 100% sensitivity but had lower than expected PPV due to LBW-related false positives. Leveraging the finding that all true positives had elevated 21-deoxycortisol while 99.2% of LBW false positives had undetectable 21DOC, a refined algorithm reduced LBW recalls by >99% and increased PPV to 87–89%, confirmed by retrospective validation in 946,246 newborns.
Impact: Defines a pragmatic, scalable LC-MS/MS algorithm that dramatically improves 21OHD screening specificity in LBW infants without sacrificing sensitivity, with immediate applicability to public health programs.
Clinical Implications: Programs can adopt a 21DOC-first exclusion criterion (with 11DOC/17OHP safeguard) to reduce recalls and parental anxiety, streamline confirmatory testing, and improve PPV while maintaining sensitivity.
Key Findings
- Prospective LC-MS/MS algorithm achieved 100% sensitivity but lower PPV due to LBW false positives (75.7% of initial positives).
- All true positives had elevated 21-deoxycortisol; 99.2% of LBW false positives had undetectable 21DOC.
- Refined algorithm (low 21DOC cutoff plus 11DOC/17OHP ratio) reduced LBW-related recalls by >99% and raised PPV to 87.2% (initial) and 89.1% (final).
Methodological Strengths
- Very large-scale prospective evaluation with extensive retrospective validation
- Targeted steroid profiling by LC-MS/MS with clear, actionable cutoffs
Limitations
- Single-region implementation (Tokyo) may limit generalizability across diverse populations and laboratory settings
- Operational cost and access to LC-MS/MS could be barriers in some programs
Future Directions: Multicenter prospective adoption studies across diverse populations; cost-effectiveness analyses; harmonization of 21DOC cutoffs and QA/QC standards.
CONTEXT: Newborn screening (NBS) for 21-hydroxylase deficiency (21OHD) has historically shown high false positive (FP) rates, especially in low birth weight (LBW) infants. In 2022, we proposed a second-tier liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based algorithm to improve screening specificity; however, its real-world performance remains unassessed prospectively. OBJECTIVE: To prospectively evaluate our LC-MS/MS-based screening algorithm for 21OHD and develop a refined version addressing newly i
3. Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.
Across six RCTs (n=1,272), survodutide significantly reduced HbA1c (WMD −0.66%), fasting glucagon (−7 pmol/L), body weight (−6.7 kg), and waist circumference (−7.09 cm) versus placebo, with stronger effects at doses >2.4 mg weekly and durations >16 weeks. Benefits extended to BMI and modest lipid/blood pressure improvements, but GI adverse events increased and led to more discontinuations, without excess serious AEs.
Impact: Provides the first consolidated RCT evidence for a GLP-1/glucagon dual agonist’s glycemic and weight efficacy with dose–duration response and safety trade-offs, informing trial design and clinical adoption.
Clinical Implications: Survodutide may be considered for adults needing intensive weight loss and glycemic improvement, with careful dose titration and monitoring for GI tolerability; longer treatment enhances effect size.
Key Findings
- HbA1c decreased by −0.66% and fasting glucagon by −7 pmol/L vs placebo.
- Body weight (−6.7 kg) and waist circumference (−7.09 cm) reductions were significant, larger at >2.4 mg/week and >16 weeks.
- BMI, total cholesterol, triglycerides, and blood pressure showed modest improvements.
- Higher discontinuation due to GI adverse events; no increase in serious adverse events.
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials with dose and duration subgroup analyses
- Comprehensive database search including ClinicalTrials.gov
Limitations
- Short-to-intermediate trial durations; long-term efficacy and safety remain uncertain
- Total sample size remains modest; heterogeneity and publication bias assessments not detailed
Future Directions: Head-to-head trials versus established incretin agents; long-term cardiovascular, renal, and ophthalmic outcomes; strategies to mitigate GI intolerance.
AIM: This meta-analysis aimed to evaluate the efficacy and safety of survodutide on glycemic control and weight loss in adults. METHODS: We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025. The primary outcomes were changes in glycated haemoglobin (HbA1c), fasting glucagon levels, body weight, waist circumference, along with the incidence of adverse e